Status:
COMPLETED
Comparison of Biocompatibility of Plasmapheresis Procedures With Citrate and Heparin Anticoagulation
Lead Sponsor:
University Medical Centre Ljubljana
Conditions:
Apheresis
Anticoagulation
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Membrane plasmapheresis is one of the methods for treating immune diseases. Plasmapheresis removes autoantibodies and immune complexes, paraproteins, lipoproteins and reduces the concentration of cyto...
Detailed Description
Standard heparin or citrate is routinely used as a method of anticoagulation in plasmapheresis. Citrate provides effective anticoagulation that is completely limited to extracorporeal circulation. Pat...
Eligibility Criteria
Inclusion
- older than 18 years
- an indication for plasma exchange (plasmapheresis) with albumin solution as a replacement solution
Exclusion
- contraindication for systemic heparinisation
- acute bleeding
- known active malignancy
- severe infection
- anticoagulant therapy at therapeutic dose
Key Trial Info
Start Date :
January 21 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2022
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05191290
Start Date
January 21 2022
End Date
December 30 2022
Last Update
November 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Ljubljana
Ljubljana, Slovenia, 1210